GeneDX Stock Drops Sharply After Disappointing Earnings and Guidance Cut

GeneDX (NASDAQ: WGS) stock fell nearly 49% on May 5, 2026 after the company reported first-quarter results that missed Wall Street expectations. The biotech firm also cut its full-year sales guidance significantly.

By Keith Noonan, The Motley Fool Tue, May 5, 2026 at 6:23 PM GMT+3 2 min read · Yahoo Finance · May 5, 2026, 15:23 UTC

GeneDX Stock Drops Sharply After Disappointing Earnings and Guidance Cut

Tickers: $INTC $NVDA $WGS

Topics: biotech financial_results stock_drop

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC